Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate

Biotech Targets Triple-Negative Breast Cancer and Lymphoma

The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.

Merck KGaA Darmstadt — Merck KGaA has licensed the drug to Diaccurate, but will maintain an active interest in the compound, and has taken a stakeholding in the biotech.

Merck KGaA has licensed to French biotech Diaccurate a PAM inhibitor candidate which could treat a broad range of tumors, including triple-negative breast cancer (TNBC) and relapsed/refractory B-cell and T-cell lymphomas.

For Merck KGaA, the deal frees up space in its cancer-dominated pipeline, and for Paris-based Diaccurate it adds a more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.